SCHEMBL3458946

SCHEMBL3458946

O=C1C(Cc2c(Cl)cc(-c3ccc(S(=O)(=O)N4CCOCC4)cc3)cc2Cl)CCN1[C@@H]1CCc2[nH]cnc2C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.37
IKBKB O14920 4/20 0.36
GAA P10253 2/20 0.36
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
KMT2A Q03164 1/20 0.36
ALDH1A1 P00352 6/20 0.36
KDM4E B2RXH2 5/20 0.36
HSD17B10 Q99714 2/20 0.36
USP2 O75604 1/20 0.36
CHUK O15111 1/20 0.35
MAPK8 P45983 1/20 0.35
MAPK9 P45984 1/20 0.35
MAPK10 P53779 1/20 0.35
MAPK11 Q15759 1/20 0.35
MAPK14 Q16539 1/20 0.35
TDO2 P48775 1/20 0.34
PLAU P00749 1/20 0.34
KCNH2 Q12809 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3458949 1.00 JAK2 (0.37) JAK2IKBKBGAAMEN1POLB
SCHEMBL3458944 1.00 JAK2 (0.37) JAK2IKBKBGAAMEN1POLB
SCHEMBL13109213 0.93 HTR2B (0.34) IKBKBGAAMEN1KMT2AALDH1A1
SCHEMBL3454276 0.92 HTR2B (0.34) IKBKBGAAMEN1POLBKMT2A
SCHEMBL3454272 0.92 HTR2B (0.34) IKBKBGAAMEN1POLBKMT2A
SCHEMBL3454274 0.92 HTR2B (0.34) IKBKBGAAMEN1POLBKMT2A
SCHEMBL3453287 0.89 PIK3CA (0.36) JAK2ALDH1A1KDM4EHPGD
SCHEMBL3453284 0.89 PIK3CA (0.36) JAK2ALDH1A1KDM4EHPGD
SCHEMBL3453285 0.89 PIK3CA (0.36) JAK2ALDH1A1KDM4EHPGD
SCHEMBL3454743 0.88 PTGS2 (0.32) JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029576-B1 CYCLOHEXYLIMIDAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2013-06-19 EP claimed
US-7820659-B2 Cyclohexylimidiazole lactam derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2010-10-26 US claimed
US-20090088428-A1 CYCLOHEXYLIMIDIAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY 2009-04-02 US claimed
EP-2029576-B1 CYCLOHEXYLIMIDAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2013-06-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088428-A1 CYCLOHEXYLIMIDIAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD17B1, HSD11B2 JAK2 3419/4885IKBKB 612/4885GAA 986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.